DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $836,436 | -2.7% | 3,371 | -5.9% | 0.08% | -1.3% |
| Q2 2023 | $859,680 | -4.8% | 3,582 | 0.0% | 0.08% | -12.4% |
| Q1 2023 | $902,807 | -33.9% | 3,582 | -30.4% | 0.09% | -39.5% |
| Q4 2022 | $1,366,046 | -1.4% | 5,147 | -4.1% | 0.15% | -9.8% |
| Q3 2022 | $1,386,000 | +1.8% | 5,368 | 0.0% | 0.16% | +8.7% |
| Q2 2022 | $1,361,000 | -13.6% | 5,368 | 0.0% | 0.15% | -2.0% |
| Q1 2022 | $1,575,000 | -9.5% | 5,368 | +1.4% | 0.15% | -1.3% |
| Q4 2021 | $1,741,000 | +27.5% | 5,293 | +5.0% | 0.16% | +10.7% |
| Q3 2021 | $1,366,000 | +20.5% | 5,043 | +19.4% | 0.14% | +18.6% |
| Q2 2021 | $1,134,000 | +47.5% | 4,224 | +23.7% | 0.12% | +3.5% |
| Q1 2021 | $769,000 | +0.9% | 3,416 | -0.4% | 0.11% | -5.8% |
| Q4 2020 | $762,000 | +25.5% | 3,430 | +21.7% | 0.12% | +10.0% |
| Q3 2020 | $607,000 | +38.6% | 2,818 | +13.8% | 0.11% | +26.4% |
| Q2 2020 | $438,000 | +27.7% | 2,477 | 0.0% | 0.09% | +6.1% |
| Q1 2020 | $343,000 | -9.7% | 2,477 | 0.0% | 0.08% | +9.3% |
| Q4 2019 | $380,000 | +6.1% | 2,477 | 0.0% | 0.08% | +1.4% |
| Q3 2019 | $358,000 | +14.7% | 2,477 | +13.5% | 0.07% | +17.5% |
| Q2 2019 | $312,000 | +8.3% | 2,183 | 0.0% | 0.06% | +6.8% |
| Q1 2019 | $288,000 | – | 2,183 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RobecoSam USA, Inc. | 74,961 | $7,572,000 | 9.43% |
| Corvid Peak Capital Management, LLC | 250,000 | $25,250,000 | 8.54% |
| CORTLAND ASSOCIATES INC/MO | 310,508 | $31,361,000 | 6.88% |
| Southpoint Capital Advisors LP | 1,250,000 | $126,250,000 | 6.75% |
| GREEN VALLEY INVESTORS LLC | 2,168,594 | $219,027,000 | 6.70% |
| DAVIS-REA LTD. | 75,080 | $7,595,000 | 5.39% |
| CADINHA & CO LLC | 247,143 | $24,961,000 | 5.35% |
| Espalier Global Management LLC | 47,100 | $4,757,000 | 5.25% |
| Spears Abacus Advisors LLC | 398,334 | $40,232,000 | 5.10% |
| GCA INVESTMENT MANAGEMENT, LLC | 158,064 | $15,964,000 | 5.01% |